Literature DB >> 2198278

Identification of HPV-16 E7 peptides that are potent antagonists of E7 binding to the retinoblastoma suppressor protein.

R E Jones1, R J Wegrzyn, D R Patrick, N L Balishin, G A Vuocolo, M W Riemen, D Defeo-Jones, V M Garsky, D C Heimbrook, A Oliff.   

Abstract

Complex formation between the human papilloma virus type-16 E7 protein (HPV-16 E7) and the retinoblastoma suppressor protein (pRB) is believed to be important in the process of cellular transformation that leads to cervical carcinoma. Utilizing an in vitro solution assay as well as a plate binding assay that measures the association between HPV-16 E7 and pRB proteins, we have examined a series of synthetic HPV-16 E7 peptides. HPV-16 E7 peptides which lie between amino acid residues 14 and 32 were found to be potent inhibitors of E7/pRB binding. The minimal peptide structure that possessed full antagonist activity was N-acetyl-E7-(21-29)-peptide amide. This peptide inhibited 100% of E7/pRB binding and exhibited an IC50 of 40 nM in the plate binding assay. A purified beta-galactosidase-E7 fusion protein exhibited an IC50 of 2 nM in the same assay. These results suggest that other regions of the E7 molecule in addition to amino acids 21-29 may contributed to E7/pRB interaction. Analysis of E7-(20-29)-peptides containing single amino acid substitutions suggests that Cys24, Tyr23, Tyr25, Asp21, and Glu26 are important residues for maintaining maximal antagonist activity. This series of peptides should prove useful in analyzing the biological consequences of E7/pRB binding in HPV-infected cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2198278

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Mutagenesis of the pRB pocket reveals that cell cycle arrest functions are separable from binding to viral oncoproteins.

Authors:  F A Dick; E Sailhamer; N J Dyson
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

2.  Clefts, grooves, and (small) pockets: the structure of the retinoblastoma tumor suppressor in complex with its cellular target E2F unveiled.

Authors:  Karl Munger
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-26       Impact factor: 11.205

3.  Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins.

Authors:  N Dyson; P Guida; K Münger; E Harlow
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

4.  Adenovirus E1A makes two distinct contacts with the retinoblastoma protein.

Authors:  N Dyson; P Guida; C McCall; E Harlow
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

5.  Cloning and characterization of E2F-2, a novel protein with the biochemical properties of transcription factor E2F.

Authors:  M Ivey-Hoyle; R Conroy; H E Huber; P J Goodhart; A Oliff; D C Heimbrook
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

6.  The binding domain structure of retinoblastoma-binding proteins.

Authors:  J Figge; K Breese; S Vajda; Q L Zhu; L Eisele; T T Andersen; R MacColl; T Friedrich; T F Smith
Journal:  Protein Sci       Date:  1993-02       Impact factor: 6.725

7.  A competitive inhibitor assay for SV40 T/pRB complex formation employing extracts of SV40-transformed human lung cells.

Authors:  K Breese; T Friedrich; J Figge
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-12       Impact factor: 2.416

8.  Modeling and molecular dynamics of the intrinsically disordered e7 proteins from high- and low-risk types of human papillomavirus.

Authors:  Nilson Nicolau; Silvana Giuliatti
Journal:  J Mol Model       Date:  2013-07-18       Impact factor: 1.810

9.  Papillomavirus E7 protein binding to the retinoblastoma protein is not required for viral induction of warts.

Authors:  D Defeo-Jones; G A Vuocolo; K M Haskell; M G Hanobik; D M Kiefer; E M McAvoy; M Ivey-Hoyle; J L Brandsma; A Oliff; R E Jones
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

10.  Purification and characterization of human papillomavirus type 16 E7 protein with preferential binding capacity to the underphosphorylated form of retinoblastoma gene product.

Authors:  Y Imai; Y Matsushima; T Sugimura; M Terada
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.